BioSpace News Archive

Specialty cancer diagnostics company Precipio, Inc., announces that it has entered into a collaboration agreement with a NY-based academic healthcare institution to jointly develop a panel for Glioblastoma, an aggressive brain cancer based on Precipio’s HemeScreen technology.

Oshi Health announced strategic investments by the American College of Gastroenterology and the American Gastroenterological Association GI Opportunity Fund.

Curebase, a company committed to democratizing access to clinical studies and a leader in decentralized clinical trial execution, is now offering Omnisite™, a flexible site model that leverages a number of the company’s existing capabilities to reach patients where they are at home and in real-world medical settings.

PharmaLogic Holdings Corp. and Evergreen Theragnostics, Inc., announced their agreement for PharmaLogic to prepare, sell, and distribute OCTEVY™, if approved by the United States Food & Drug Administration, to their extensive network of PET customers across the country.

Beaconcure, Inc., the leading clinical data technology and automation company, announced the closing of its $14 million Series B financing round.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces the approval of all resolutions proposed at its Annual General Meeting held at its headquarters in Liège, Belgium on 13 June 2023.

Comanche Biopharma is pleased to announce the appointment of Ann Taylor, M.D. to its Board of Directors.

Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has approved Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome (ALGS).

Report reveals initial deployment of legacy systems has paved the way for imminent shift to modern software needed to accelerate AI-powered drug R&D

Heligenics, a cutting-edge biotech company, announces a first-of-its-kind precision genetic test to select among drugs to treat breast cancer.